Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Precision Therapy in Refractory Tumor (Long March Pathway)

NCT03239015 is registered in ClinicalTrials.gov with Baodong Qin as lead sponsor.

NCT NCT03239015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03239015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Precision Therapy in Refractory Tumor (Long March Pathway)
Lead sponsor
Baodong Qin
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2017
Completion date
December 31, 2023
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rare tumor, refractory tumor